Results 221 to 230 of about 42,502 (303)

THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) AS TREATMENT OF DEPRESSION IN PATIENTS WITH EPILEPSY

, 2016
Yu. V. Solomatin, Yu. V. Rubleva
openalex   +2 more sources

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 545-555, February 2026.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Fetal behavior and gestational serotonin reuptake inhibitor exposure: relationships between behavior, drug dosage, plasma drug level, and a measure of drug bioeffect. [PDF]

Neuropsychopharmacology
Salisbury AL, Anderson GM, Yang A, Stika CS, Rasmussen-Torvik LJ, Gollan JK, Wisner KL.   +6 more
europepmc   +1 more source

From Struggling (With) Screening Tests to Mouse Models of Depression‐Relevant Neurobehavioral States

Current Protocols, Volume 6, Issue 2, February 2026.
Abstract A major, serendipitous psychiatric discovery is monoamine‐transporter reuptake inhibition as an antidepressant mechanism of action. Chronic treatment with such antidepressants is efficacious, with onset requiring 1‐2 weeks, in many but by no means all patients with major depressive or another stress‐related neuropsychiatric disorder.
Christopher R. Pryce
wiley   +1 more source

Development and Validation of the Brief Inventory of Treatment Expectations in Chronic Pain (BITEC)

European Journal of Pain, Volume 30, Issue 2, February 2026.
ABSTRACT Background Expectations shape therapeutic outcomes, yet their systematic assessment remains limited in clinical and research settings. To address this gap, we developed and validated the Brief Instrument for the Assessment of Treatment Expectations in Chronic Pain (BITEC) using Item Response Theory. Methods The study comprised four phases. (I)
Wolnei Caumo, Bárbara Regina França, Jaira Ehlers, Stela Maris de Jezus Castro, Rogério Boff Borges, Vania Naomi Hirakata, Graziele Borges Bueno, Iraci LS da Torres, Felipe Fregni   +8 more
wiley   +1 more source

The selective serotonin reuptake inhibitor paroxetine improves right ventricular systolic function in experimental pulmonary hypertension. [PDF]

J Mol Cell Cardiol Plus
Waddingham MT, Tsuchimochi H, Sonobe T, Sequeira V, Nayeem MJ, Shirai M, Pearson JT, Ogo T.   +7 more
europepmc   +1 more source

Molecular and Transcriptional Signatures of Gray Matter Volume Alterations Associated With Depressive Symptoms in Mild Cognitive Impairment

Human Brain Mapping, Volume 47, Issue 2, February 1, 2026.
Morphological alterations related to depressive symptoms in mild cognitive impairment were primarily involved in emotion and affective processing, showing strong correspondence with serotonergic, dopaminergic, and GABAergic systems and enrichment of genes associated with synaptic function and excitatory neurons.
Hu Xu, Yang Li, Chensi Li, Fenglin Xu, Yun Liu, Kehan Yan, Shiyi Chen, Wenxiu Song, Yifeng Luo, Yuefeng Li   +9 more
wiley   +1 more source